HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

zolpidem (Ambien)

an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; benzodiazepine receptor agonist; RN given from Toxline; RN not in Chemline 12/85; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; structure given in first source

Also Known As:

Ambien; Stilnox; zolpidem tartrate; 1A brand of zolpidem tartrate; AWD brand of zolpidem tartrate; AbZ brand of zolpidem tartrate; Allphar brand of zolpidem tartrate; Amsic; Atlanta Pharma brand of zolpidem tartrate; BC brand of zolpidem tartrate; Bikalm; Dalparan; Farma Lepori brand of zolpidem tartrate; Hexal brand of zolpidem tartrate; Krewel brand of zolpidem tartrate; Lichtenstein brand of zolpidem tartrate; Merck dura brand of zolpidem tartrate; N,N,6-trimethyl-2-(4-methylphenyl)imidazo(1,2a)pyridine-3-acetamide hemitartrate; SL 80.0750; SL-800750-23-N; Sanofi Synthelabo brand of zolpidem tartrate; Sanofi brand of zolpidem tartrate; Stilnoct; Zoldem; Zolirin; Zolpi-Lich; Zolpidem 1A Pharma; Zolpidem AbZ; Zolpinox; zodormdura

Networked: 466 relevant articles (63 outcomes, 92 trials/studies) for this Drug, Comments

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 37
- 1-Ring Heterocyclic Compounds
  - Pyridines: 36
    - zolpidem: 466

Experts

1.	Roth, Thomas: 6 articles (04/2012 - 09/2008)
2.	Staner, Luc: 4 articles (08/2012 - 10/2005)
3.	Clauss, R P: 3 articles (10/2012 - 01/2000)
4.	Roehrs, Timothy A: 3 articles (08/2012 - 01/2009)
5.	Lundahl, Jonas: 3 articles (08/2012 - 05/2007)
6.	Cook, James M: 3 articles (04/2012 - 03/2005)
7.	Asnis, Gregory M: 3 articles (07/2011 - 01/2006)
8.	Walsh, James K: 3 articles (06/2008 - 10/2002)
9.	Nel, H W: 2 articles (10/2012 - 01/2000)
10.	Kao, Chia-Hung: 2 articles (06/2012 - 05/2012)

Related Diseases

1.	Sleep Initiation and Maintenance Disorders (Insomnia) 01/01/2010 - "Zolpidem is clinically very effective in treating insomnia. " 05/18/2007 - "Zolpidem has been known as a very safe and effective hypnotic drug used to treat a variety of patients with insomnia. " 08/01/2004 - "Over a period of 12 weeks of intermittent treatment with zolpidem, sleep continuity was significantly improved, the clinical gains were sustained, and there was no evidence of subjective rebound insomnia between doses or increases in the amount of medication used during the study interval." 10/01/2008 - "Employed adults with chronic insomnia treated with zolpidem extended-release 12.5 mg experienced significantly improved work performance over 24 weeks." 12/15/2000 - "In agreement with previous findings obtained in patients with chronic primary insomnia, zolpidem significantly improved sleep induction and maintenance. " Order ALL the reference details at left...
2.	Brain Injuries (Brain Injury) 08/01/2004 - "The authors postulate a central mechanism of action by selective inhibition of GABAergic inhibitory neurons, and suggest a controlled clinical study to investigate the potential efficacy of zolpidem in relieving spasticity related to postanoxic brain injury." 01/01/2004 - "After zolpidem, cerebral perfusion through brain injury areas improved substantially in three patients and the cerebellar diaschisis was reversed. " 01/01/2008 - "This study treated a 44 year old male with MCS some 4 years after his traumatic brain injury with zolpidem for 1 week on and 1 week off treatment. " 01/01/2004 - "The study investigates the effect of zolpidem (CAS 82626-48-0) on brain injuries and cerebellar diaschisis. " 10/01/2012 - "A 27-year-old neurologically disabled but fully conscious male zolpidem-responder patient was investigated for blood brain barrier (BBB) dysfunction 5 years after a traumatic brain injury. " Order ALL the reference details at left...
3.	Dystonia (Limb Dystonia) 01/01/2012 - "To investigate what subtype of dystonia is responsive to the therapy, we conducted an open label study to assess the efficacy of zolpidem (5-20 mg) in 34 patients suffering from miscellaneous types of dystonia using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS). " 01/01/2012 - "Efficacy of zolpidem for dystonia: a study among different subtypes." 01/01/2012 - "In conclusion, our large scale study suggested that zolpidem may be a therapeutic option for dystonia, particularly post-traumatic dystonia." 01/01/2012 - "We conducted an open-label study to assess the efficacy of zolpidem in 34 patients with primary dystonia patients, The Burke Fahn Marsden Dystonia Rating Scale (BFMDRS) scores in the patients were decreased from 7.2±7.9 to 5.5±5.0 after zolpidem therapy (P=0.042). " 01/01/2012 - "Next we evaluated 55 patients with primary and secondary dystonia, 16 of 55 patients (29%) responded to zolpidem, and secondary dystonia, particularly post-traumatic dystonia, was more responsive than primary dystonia (5 of 11 [46%] vs 11 of 44 [25%]). " Order ALL the reference details at left...
4.	Sleep Disorders 07/01/2002 - "With discontinuation of zolpidem and effective treatment of their sleep disorders, nocturnal eating resolved. " 04/01/1992 - "The safety and efficacy of 10 or 20 mg/day zolpidem, a new hypnotic belonging to the imidazopyridine class, were studied over a 180-day period in 96 patients with sleep disorders. " 01/01/2010 - "Zolpidem is a hypnotic drug used in sleep disorders. " 01/01/2004 - "Use of zolpidem in over 75-year-old patients with sleep disorders and comorbidities." 07/01/2002 - "Zolpidem, at least in patients with underlying sleep disorders that cause frequent arousals, may cause or augment sleep-related eating behavior. " Order ALL the reference details at left...
5.	Substance Withdrawal Syndrome (Withdrawal Symptoms) 03/01/2011 - "Several recent reports attest to zolpidem's strong potential for abuse, dependence, and severe withdrawal symptoms upon its discontinuation. " 09/01/2004 - "A case of parenteral zolpidem dependence with opioid-like withdrawal symptoms." 08/30/1993 - "Adverse effects such as withdrawal symptoms, dependence and abuse have not previously been reported in relation to zolpidem. " 08/30/1993 - "Withdrawal symptoms and ultimately psychosis developed in two cases following cessation of the hypno-sedative zolpidem. " 04/01/1992 - "Zolpidem was well tolerated with no withdrawal symptoms during the second 7-day placebo treatment period. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Benzodiazepines
2.	zaleplon (Sonata)
3.	Triazolam (Halcion)
4.	zopiclone (Zop)
5.	Hypnotics and Sedatives (Sedatives)
6.	Flunitrazepam (Rohypnol)
7.	Citalopram (Escitalopram)
8.	Nitrazepam (Serenade)
9.	GABA-A Receptors (GABA(A) Receptor)
10.	Temazepam (Nocturne)

Related Therapies and Procedures

1.	Continuous Positive Airway Pressure
2.	Aftercare (After-Treatment)
3.	Drug Therapy (Chemotherapy)
4.	Investigational Therapies (Experimental Therapy)
5.	Oral Administration

blog comments powered by Disqus

TREATMENT OPTIONS
for Sleep Initiation and Maintenance Disorders,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 407 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>